| 摘要 |
The present invention provides individual crystalline polymorphs of 7-(tert-Butyl-d9)-3-(2,5-difluorophenyl)-6-((1-methyl-1H-1,2,4-triazol-5-yl)methoxy)-[1,2,4]triazolo[4,3-b]pyridazine designated Form 5. The Form 5 polymorph disclosed herein is characterized according to one or more of (a) powder X-ray diffraction data (“XRPD”); (b) differential scanning calorimetry (“DSC”); (c) FT-Raman spectroscopy; (d) FT-IR spectroscopy; and (e) thermogravimetric analysis (TGA). |
| 主权项 |
1. A polymorph of an optionally deuterated 7-(tert-Butyl)-3-(2,5-difluorophenyl)-6-((1-methyl-1H-1,2,4-triazol-5-yl)methoxy)-[1,2,4]triazolo[4,3-b]pyridazine characterized by at least one of:
a. a powder X-ray diffraction pattern having two or more peaks expressed in degrees 2-theta±0.2° and selected from about 6.81, 7.27, 8.19, 9.76, 10.87, 14.65, 14.78, 15.43, 15.68, 16.77, 16.90, 17.09, 19.66, 21.90, 22.00, 22.26, 22.52, 26.34, 27.85, 29.63, 29.78, and 33.23 degrees; or b. a DSC thermogram showing an onset at about 204° C. |
